Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
The European Commission has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab) for treating adults with advanced basal cell carcinoma (BCC) who have progressed on or are intolerant to hedgehog pathway inhibitors. This decision is based on the largest trial to date, indicating an objective response rate of 32% for locally advanced BCC and 29% for metastatic BCC. Notably, approximately 90% of patients experienced a duration of response of 6 months or longer. Libtayo is now approved for three advanced cancers in the EU, enhancing treatment options for challenging cases.
The European Commission has approved Regeneron and Sanofi's Libtayo® (cemiplimab) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression. The approval is based on a Phase 3 trial showing Libtayo extends median overall survival by 8 months compared to chemotherapy and reduces the risk of death by 32%. Libtayo is now approved for three advanced cancers in the EU, with a consistent safety profile and no new safety signals reported.
Regeneron Pharmaceuticals (NASDAQ: REGN) will participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series on June 29, 2021, at 10:00 a.m. ET. The event will focus on global strategy and innovation in biopharma.
A live audio webcast can be accessed via Regeneron's 'Investors and Media' webpage, with an archived replay available for 30 days post-event. Regeneron is renowned for its innovative medicines addressing serious diseases, with a robust pipeline supported by advanced technologies like VelociSuite®.
Regeneron's investigational treatment, REGEN-COV, demonstrated a 20% reduction in mortality among hospitalized COVID-19 patients without an immune response, according to the UK RECOVERY trial. This landmark study marks the first evidence that any monoclonal antibody therapy can improve survival rates in severe cases. REGEN-COV significantly shortened hospital stays by an average of 4 days and increased the likelihood of discharge alive at day 28. Regeneron plans to expand its Emergency Use Authorization (EUA) to include these patients, aiming for broader access to this effective therapy.
Regeneron Pharmaceuticals announced the FDA's updated Emergency Use Authorization (EUA) for REGEN-COV™, lowering the dose to 1,200 mg, which reduces the risk of hospitalization or death by 70%. REGEN-COV remains the only antibody therapy available in all 50 states and is provided free of charge by the U.S. government. The updated EUA is based on pivotal Phase 3 data showing its effectiveness against COVID-19 variants. Regeneron expects to submit a full Biologics License Application later this summer and plans to deliver at least 1 million doses to the government in Q2 2021.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi announced that the EMA's CHMP has issued positive opinions for Libtayo (cemiplimab) as a first-line treatment for advanced non-small cell lung cancer (NSCLC) and for advanced basal cell carcinoma (BCC). Libtayo is recommended for NSCLC patients with ≥50% PD-L1 expression and without specific genetic aberrations. The recommendation for BCC comes after patients have progressed on or are intolerant to hedgehog pathway inhibitors. The European Commission will decide on these applications soon.
Regeneron Pharmaceuticals (REGN) announced Michelle Hua, 16, as the top prize winner at the 2021 Regeneron International Science and Engineering Fair, receiving a $75,000 award for her innovative AI algorithm in human action recognition. This year marked the event's first virtual format, showcasing over 1,800 young scientists from 49 states and 64 countries. Over $5 million in total prizes were awarded. The initiative aims to inspire young STEM leaders, highlighting the importance of scientific inquiry, especially during the COVID-19 pandemic.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced positive clinical data for the combination of fianlimab (LAG-3 inhibitor) and Libtayo (cemiplimab) in advanced melanoma, achieving a 64% objective response rate in PD-1 inhibitor naïve patients. Upcoming presentations at the ASCO Annual Meeting from June 4-8 will cover various cancers, including lung and skin cancers, focusing on Libtayo's impact on quality of life. An investor webcast is scheduled for June 7 to discuss further updates on its oncology portfolio.
Regeneron Pharmaceuticals reported promising results from its Phase 3 trial of REGEN-COV, demonstrating significant efficacy in treating high-risk COVID-19 outpatients. Patients receiving REGEN-COV experienced a 70-71% reduced risk of hospitalization or death and a 4-day shorter symptom duration compared to placebo. The U.S. FDA is reviewing a request to authorize a lower 1,200 mg dose. The trial involved 4,567 participants, highlighting the treatment's potential for individuals with conditions like asthma and obesity. Safety assessments showed a low rate of serious adverse events.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
What types of diseases does Regeneron Pharmaceuticals focus on?
What are some of Regeneron's key products?
Who are some of Regeneron's notable collaborators?
What recent financial steps has Regeneron taken?
How does Regeneron leverage genetic medicine?
What is the significance of Eylea in Regeneron's product portfolio?
What advancements has Regeneron made in gene therapy?
What is Dupixent used for?
What technologies does Regeneron use for drug development?
How does Regeneron contribute to scientific discovery?
